Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 7Melanoma 4Colitis 3Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Lung Neoplasms 2Inflammatory Bowel Diseases 2Inflammation 2Fatigue 2Depressive Disorder, Major 2Depression 2Colitis, Ulcerative 2Vasculitis 1Takayasu Arteritis 1Syndrome 1Stroke 1Stevens-Johnson Syndrome 1Spondylitis, Ankylosing 1Skin Neoplasms 1Psoriasis 1Precancerous Conditions 1Pemphigoid, Benign Mucous Membrane 1Infections 1Hypertension 1Hepatitis C 1Hematologic Neoplasms 1Graft vs Host Disease 1Drug-Related Side Effects and Adverse Reactions 1Depressive Disorder, Treatment-Resistant 1Cytokine Release Syndrome 1

Interventions

Exercise 6Transcranial Direct Current Stimulation 4Neuropsychological Tests 4Walking 3Memantine 3Tablets 2Standard of Care 2Patient Reported Outcome Measures 2Methods 2Electroencephalography 2Donepezil 2Cognitive Behavioral Therapy 2mazdutide 1lime 1enzalutamide 1blueberry extract 1beta Carotene 1acetaminophen, aspirin, caffeine drug combination 1Vitamin E 1Vitamin D 1Ultraviolet Therapy 1Transcranial Magnetic Stimulation 1Time 1Therapeutics 1Tai Ji 1Surveys and Questionnaires 1Sugars 1Sodium Chloride 1Sirolimus 1Silymarin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cognitive Dysfunction × Infliximab × Clear all
NCT06136546 2025-05-07

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

Massachusetts General Hospital

Phase 2 Recruiting
100 enrolled

Depression, Depressive Disorder, Major, Inflammation, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡